In the latest trading session, 4.3 million TransCode Therapeutics Inc (NASDAQ:RNAZ) shares changed hands as the company’s beta touched 1.02. With the company’s most recent per share price at $10.14 changing hands around $3.98 or 64.61% at last look, the market valuation stands at $7.06M. RNAZ’s current price is a discount, trading about -554.14% off its 52-week high of $66.33. The share price had its 52-week low at $2.66, which suggests the last value was 73.77% up since then. When we look at TransCode Therapeutics Inc’s average trading volume, we note the 10-day average is 6.56 million shares, with the 3-month average coming to 1.14 million.
TransCode Therapeutics Inc (NASDAQ:RNAZ) trade information
Instantly RNAZ is in green as seen in intraday trades today. With action 20.71%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 200.89%, with the 5-day performance at 20.71% in the green. However, in the 30-day time frame, TransCode Therapeutics Inc (NASDAQ:RNAZ) is 178.57% up. Looking at the short shares, we see there were 0.74 million shares sold at short interest cover period of 0.5 days.
TransCode Therapeutics Inc (RNAZ) estimates and forecasts
Data shows that the TransCode Therapeutics Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 18.82% over the past 6 months, a 99.86% in annual growth rate that is considerably higher than the industry average of 18.00%.
Consensus estimates given by 1 financial analysts project the company’s revenue in the current quarter to hit an average of 300k. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -28.81%. The 2025 estimates are for TransCode Therapeutics Inc earnings to increase by 99.86%.
RNAZ Dividends
TransCode Therapeutics Inc is expected to release its next quarterly earnings report in March.
TransCode Therapeutics Inc (NASDAQ:RNAZ)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 0.01% of TransCode Therapeutics Inc shares while 1.99% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 1.99%.
Among Mutual Funds, the top two as of Nov 30, 2024 were Fidelity Extended Market Index Fund and Fidelity Total Market Index Fund. With 2.89 shares estimated at $31644.0 under it, the former controlled 0.41% of total outstanding shares. On the other hand, Fidelity Total Market Index Fund held about 0.17% of the shares, roughly 1.18 shares worth around $12933.0.
